W
WAVEMAN · COMPANY
PTHS · Pelthos Therapeutics Inc.
> Ask across nine datasets ⌘K
LIVE
TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475
← ALL COMPANIES

PTHS

Pelthos Therapeutics Inc.
PHARMA & BIOTECH · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · CIK 0001919246
SEC FILINGS☆ WATCH
INSIDER NET · 180D
$838.8K
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
1
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
16
13F, latest reported quarter
REVENUE GROWTH
-
XBRL, annual
NET MARGIN
-257.9%
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net +$838.8K over 180 days
+$936.2K over 90 days
more than 87% of Pharma & Biotech
CONGRESS
no member of Congress has reported trading it
FUNDS
16 funds added or opened last quarter
below 73% of Pharma & Biotech
REVENUE
no revenue reported in any filing
MARGIN
-257.9% net margin
below 76% of Pharma & Biotech
BUYBACKS
no share repurchases reported
SHORT
no short interest reported
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN +11.4%
+11.4%12M
-19%+10%+38%+67%2025-092025-102025-122026-032026-052026-072026-09 2026-06-11 · Davis Todd C bought $985.4K2025-11-25 · Friedberg Ezra M sold $168.0K2025-11-25 · Friedberg Ezra M sold $56.3K2025-11-25 · Friedberg Ezra M sold $56.0K2026-05-22 · Francis Knuettel II sold $40.3K2026-07-02 · Greenleaf Peter sold $18.5K2026-07-02 · Pauls Matthew sold $18.0K2026-06-11 · Davis Todd C bought $14.5K2026-07-02 · Friedberg Ezra M sold $13.9K2026-04-02 · Greenleaf Peter sold $8.6K2026-04-02 · Pauls Matthew sold $8.5K2026-04-02 · Greenleaf Peter sold $8.1K2026-04-02 · Pauls Matthew sold $7.9K2026-04-02 · Malamut Richard sold $6.4K2026-06-15 · Friedberg Ezra M sold $6.1K2026-04-02 · Friedberg Ezra M sold $6.0K2026-04-02 · Malamut Richard sold $6.0K2026-04-02 · Friedberg Ezra M sold $5.7K2026-07-02 · Pauls Matthew sold $2.6K2026-07-02 · Greenleaf Peter sold $2.3K2026-06-15 · Friedberg Ezra M sold $1.6K2026-07-02 · Friedberg Ezra M sold $6562025-11-25 · Friedberg Ezra M sold $28
INSIDER BUYINSIDER SELL
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
Insiders are net buyers of their own stock.
The record shows a net $838.8K bought by insiders over 180 days, 16 funds added last quarter. Every figure is a federal filing, dated the day it became public.
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Pelthos Therapeutics Inc. insiders bought a net $838.8K of stock across 23 Form 4 purchases and sales, with 1 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-05.

INSIDER
FILED
SHARES
VALUE
Friedberg Ezra M
Director
SELL
2026-07-02
534.0
$13.9K
Friedberg Ezra M
Director
SELL
2026-07-02
24.0
$656
Greenleaf Peter
Director
SELL
2026-07-02
712.0
$18.5K
Greenleaf Peter
Director
SELL
2026-07-02
85.0
$2.3K
Pauls Matthew
Director
SELL
2026-07-02
692.0
$18.0K
23 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 18 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
AIGH Capital Management LLC
329,098.0 sh
$9.3M
Murchinson Ltd.
304,302.0 sh
$8.6M
Ikarian Capital, LLC
256,598.0 sh
$7.3M
BOOTHBAY FUND MANAGEMENT, LLC
101,976.0 sh
$2.9M
VANGUARD CAPITAL MANAGEMENT LLC
97,134.0 sh
$2.7M
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
FORM 144
No planned-sale notices
No insider has notified an intent to sell. This is the panel to watch after a run-up.
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
Fidelity Extended Market Index Fund
$186.0K POSITION · AS OF 2026-02-28
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$273.0K POSITION · AS OF 2026-03-31
0.0%
VANGUARD TOTAL STOCK MARKET INDEX FUND
$1.6M POSITION · AS OF 2026-03-31
0.0%
VANGUARD BALANCED INDEX FUND
$43.9K POSITION · AS OF 2026-03-31
0.0%
Fidelity Series Total Market Index Fund
$45.5K POSITION · AS OF 2026-02-28
0.0%
Fidelity Total Market Index Fund
$54.1K POSITION · AS OF 2026-02-28
0.0%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
REVENUE$16.8M$0
OPERATING INCOME$-32.4M$-7.6M$-6.9M$-2.3M
NET INCOME$-43.3M$-8.0M$-7.4M$-2.5M
EPS (DILUTED)-23.04-14.27-5.78
OPERATING CASH FLOW$-22.6M$-5.8M$-981.0K$-1.6M
CASH$18.0M$513.0K$100.0K$100.0K
BUYBACKS$0$75.0K
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-05 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-05 ALL SYSTEMS LIVE FOR MACHINES →